ResearcherFred Hutch Cancer CenterActive in the last 2 years
Rachael Ann Safyan
Matched on ORCID iD 0000-0002-0181-6007; OpenAlex author ID A5055075354. Sources: ClinicalTrials.gov.
Their work
- Papers
- 8 (first author 1, last author 0)
- Trials
- 2 (principal investigator on 2)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 42
2021: 1 trial · 2022: none · 2023: 2 papers, 1 trial · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers
Papers 8
- Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag091↗
- Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinom… Co-author DOI 10.3390/cancers18030507↗
- Long-Term Survival Following Chemoradiation in Locoregional Recurrent Germline ATM Mutated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.adro.2025.101742↗
- Updates on molecular targets and clinical trials with targeted therapies for pancreatic cancer. Co-author DOI 10.1016/j.suronc.2025.102268↗
- HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-2200↗
- Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer. Co-author DOI 10.1200/edbk_438598↗
- Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-Wo… Co-author DOI 10.1093/oncolo/oyac217↗
- The role of molecular testing in pancreatic cancer. First author DOI 10.1177/17562848231171456↗
Trials 2
Closest collaborators
The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elena Gabriela Chiorean · 6 shared papers, 2023–2026 · strength 1.65
- Paper Updates on molecular targets and clinical trials with targeted therapies for pancreatic cancer. DOI 10.1016/j.suronc.2025.102268↗
- Paper Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer. DOI 10.1200/edbk_438598↗
- Paper Long-Term Survival Following Chemoradiation in Locoregional Recurrent Germline ATM Mutated Pancreatic Ductal Adenocarci… DOI 10.1016/j.adro.2025.101742↗
- Sita Kugel · 4 shared papers, 2025–2026 · strength 0.92
- Paper Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastati… DOI 10.1093/oncolo/oyag091↗
- Paper Long-Term Survival Following Chemoradiation in Locoregional Recurrent Germline ATM Mutated Pancreatic Ductal Adenocarci… DOI 10.1016/j.adro.2025.101742↗
- Paper Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Me… DOI 10.3390/cancers18030507↗
- Naomi Yamamoto · 2 shared papers, 2025–2026 · strength 0.45
- David Bing Zhen · 2 shared papers, 2023–2026 · strength 0.45
- Sunil R. Hingorani · 2 shared papers, 2025–2026 · strength 0.42
- Paper Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Me… DOI 10.3390/cancers18030507↗
- Paper HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-24-2200↗
- Susan Elaine Bates · 2 shared papers, 2023–2026 · strength 0.41
- Paper Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastati… DOI 10.1093/oncolo/oyag091↗
- Paper Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regre… DOI 10.1093/oncolo/oyac217↗
- Gulam Abbas Manji · 2 shared papers, 2023–2026 · strength 0.41
- Paper Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastati… DOI 10.1093/oncolo/oyag091↗
- Paper Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regre… DOI 10.1093/oncolo/oyac217↗
- Ruth Aroon White · 1 shared paper, 2026 · strength 0.26
- Jacob K.R. Jamison · 1 shared paper, 2026 · strength 0.26
- Tamas A. Gonda · 1 shared paper, 2026 · strength 0.26
- Paul E. Oberstein · 1 shared paper, 2026 · strength 0.26
- Bas Groot Koerkamp · 1 shared paper, 2024 · strength 0.24
- Andrew J. Aguirre · 1 shared paper, 2024 · strength 0.24
- Marjolein Y.V. Homs · 1 shared paper, 2024 · strength 0.24
- Venu Gopal Pillarisetty · 1 shared paper, 2025 · strength 0.24
- Jonathan G. Sham · 1 shared paper, 2025 · strength 0.24
- Dushyant V. Sahani · 1 shared paper, 2025 · strength 0.24
- Martin C. Whittle · 1 shared paper, 2026 · strength 0.23
- Andrew Eugene Hendifar · 1 shared paper, 2026 · strength 0.23
- Ben George · 1 shared paper, 2026 · strength 0.23
- Andrew L. Coveler · 1 shared paper, 2026 · strength 0.23
- Tomislav Dragovich · 1 shared paper, 2026 · strength 0.23
- Howard S. Höchster · 1 shared paper, 2026 · strength 0.23
- Nina G. Steele · 1 shared paper, 2025 · strength 0.19
- Liang‐I Kang · 1 shared paper, 2025 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.